Nadine A Friedrich
Overview
Explore the profile of Nadine A Friedrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
4
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berkowitz J, Weissenbacher D, Srinivasan A, Friedrich N, Acitores Cortina J, Kivelson S, et al.
medRxiv
. 2025 Feb;
PMID: 39990542
Large language models (LLMs) integrate knowledge from diverse sources into a single set of internal weights. However, these representations are difficult to interpret, complicating our understanding of the models' learning...
2.
Tsang K, Kivelson S, Acitores Cortina J, Kuchi A, Berkowitz J, Liu H, et al.
Annu Rev Biomed Data Sci
. 2025 Jan;
PMID: 39879559
Cancer remains a leading cause of death globally. The complexity and diversity of cancer-related datasets across different specialties pose challenges in refining precision medicine for oncology. Foundation models offer a...
3.
Friedrich N, Gu L, Waller J, De Hoedt A, Klaassen Z, Freedland S
Prostate
. 2024 Jul;
84(14):1336-1343.
PMID: 39031050
Background: There are no population-level studies assessing F-fluciclovine (fluciclovine) utilization of Positron emission tomography/computed tomography (PET/CT) for biochemically recurrent prostate cancer (PC). We assessed fluciclovine PET/CT in the Veterans Affairs...
4.
Friedrich N, Luu M, Gale R, Chaplin A, Ballas L, Sandler H, et al.
Urol Oncol
. 2024 May;
42(9):288.e7-288.e15.
PMID: 38762384
Introduction: Multidisciplinary consultations improve decisional conflict and guideline-concordant treatment for men with prostate cancer (PC), but differences in the content discussed by specialty during consultations are unknown. Methods: We audiorecorded...
5.
Galvan G, Friedrich N, Das S, Daniels J, Pollan S, Dambal S, et al.
Front Oncol
. 2024 Jan;
13:1251297.
PMID: 38188290
Introduction: We previously reported that cholesterol homeostasis in prostate cancer (PC) is regulated by 27-hydroxycholesterol (27HC) and that CYP27A1, the enzyme that converts cholesterol to 27HC, is frequently lost in...
6.
Dymanus K, Friedrich N, Howard L, Oyekunle T, De Hoedt A, Labadzhyan A, et al.
Transl Androl Urol
. 2023 Nov;
12(10):1540-1549.
PMID: 37969776
Background: Androgen deprivation therapy (ADT), commonly delivered via a luteinizing hormone-releasing hormone (LHRH) agonist, is the standard treatment for advanced prostate cancer (PC). While quite effective, it has been associated...
7.
Das S, Friedrich N, Daniels J, Galvan G, Gong J, Posadas E, et al.
Prostate Cancer Prostatic Dis
. 2023 Sep;
27(3):457-461.
PMID: 37679603
Background: There are many FDA-approved drugs for advanced prostate cancer (PC), yet public interest in these drugs is not well understood. We compared public interest and state-level predictors of interest...
8.
Daniels J, Patel D, Galvan G, Friedrich N, Das S, Akhavein A, et al.
Prostate Cancer Prostatic Dis
. 2023 Jul;
27(1):150-152.
PMID: 37422525
Understanding patient interest among surgical options is challenging. We used Google Trends to analyze interest in benign prostatic hyperplasia (BPH) surgeries recommended for prostate volumes <80 cc. Google Trends was...
9.
Galvan G, Das S, Daniels J, Friedrich N, Freedland S
Prostate Cancer Prostatic Dis
. 2023 Feb;
26(4):639-640.
PMID: 36732363
No abstract available.
10.
Galvan G, Daniels J, Friedrich N, Das S, Freedland S
Prostate Cancer Prostatic Dis
. 2023 Feb;
26(4):641-642.
PMID: 36732362
No abstract available.